CASI director reports existing option holdings

CASI Pharmaceuticals director Zeng Xuebo has filed a Form 3 disclosing existing stock option holdings.

Rhea-AI Filing Summary

CASI Pharmaceuticals director Zeng Xuebo has filed a Form 3 disclosing existing stock option holdings. The filing lists three fully vested and exercisable options, each linked to 11,231 ordinary shares.

The options carry exercise prices of $1.26, $2.67, and $1.93 per share and expire on July 21, 2035, June 18, 2034, and April 14, 2033, respectively. No new share purchases or sales are reported; the form simply records current derivative positions.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Zeng Xuebo

Role Director

Type	Security	Shares	Price	Value
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--

Holdings After Transaction: Option (right to buy) — 33,693 contracts (Direct)

Footnotes (1)

1. F1. The options are fully vested and exercisable as of the date of this form.

Key Figures

Option exercise price: $1.26 per share Option exercise price: $2.67 per share Option exercise price: $1.93 per share +1 more

4 metrics

Option exercise price $1.26 per share Option over 11,231 ordinary shares expiring July 21, 2035

Option exercise price $2.67 per share Option over 11,231 ordinary shares expiring June 18, 2034

Option exercise price $1.93 per share Option over 11,231 ordinary shares expiring April 14, 2033

Underlying shares per option 11,231 ordinary shares Per option position reported as fully vested and exercisable

Key Terms

Option (right to buy), Ordinary Share, fully vested and exercisable, Form 3

4 terms

Option (right to buy) financial

"security_title: "Option (right to buy)" for each derivative holding"

Ordinary Share financial

"underlying_security_title: "Ordinary Share" for each option position"

An ordinary share is a unit of ownership in a company that gives the holder a stake in its profits and usually the right to vote on key decisions. Think of it like a slice of a pizza where each slice entitles you to a portion of what’s left after bills are paid; value can rise or fall with the business and may pay dividends, so it matters to investors for income, growth and control.

fully vested and exercisable financial

"The options are fully vested and exercisable as of the date of this form."

Form 3 regulatory

"The options are fully vested and exercisable as of the date of this form."

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does CASI (CASIF) director Zeng Xuebo report in this Form 3?

The Form 3 shows director Zeng Xuebo’s existing stock option holdings in CASI Pharmaceuticals. It lists three fully vested options, each tied to 11,231 ordinary shares, with exercise prices between $1.26 and $2.67 and expirations from 2033 to 2035.

Are any CASI Pharmaceuticals (CASIF) shares bought or sold in this Form 3?

No share purchases or sales are reported in this Form 3. The entries are classified as holdings, with zero buy or sell transactions in the summary, and they simply disclose already outstanding, fully vested stock options held by the director.

What stock option terms does CASI (CASIF) director Zeng hold according to the filing?

The director holds three option positions over ordinary shares. Each option covers 11,231 underlying shares, with exercise prices of $1.26, $2.67, and $1.93 per share, and expiration dates in 2035, 2034, and 2033, respectively, all fully vested and exercisable.

Are the CASI Pharmaceuticals (CASIF) options reported by Zeng fully vested?

Yes, the footnote states the options are fully vested and exercisable as of the Form 3 date. This means Zeng can exercise each option immediately, subject to its individual exercise price and long-dated expiration schedule extending between 2033 and 2035.

How many CASI (CASIF) ordinary shares underlie each reported option grant?

Each of the three option positions is linked to 11,231 underlying ordinary shares. This figure appears consistently in both the individual transaction records and the derivative holdings summary, providing a clear view of the scale of each option award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/20/2026 - 09:33 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Zeng Xuebo

(Last) (First) (Middle)

SOUTH TOWER, POLY INTERNATIONAL PLAZA

NO. 1 EAST PAZHOU AVENUE, HAIZHU DIST.

(Street)

GUANGZHOU 510335

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CASI Pharmaceuticals, Inc. [ CASIF ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	(1)	04/14/2033	Ordinary Share	11,231	$1.93	D
Option (right to buy)	(1)	06/18/2034	Ordinary Share	11,231	$2.67	D
Option (right to buy)	(1)	07/21/2035	Ordinary Share	11,231	$1.26	D

Explanation of Responses:

1. The options are fully vested and exercisable as of the date of this form.

	/s/ Xuebo Zeng	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)